These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 21384525

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction.
    Castroagudín JF, Molina E, Romero R, Otero E, Tomé S, Varo E.
    Liver Transpl; 2009 Dec; 15(12):1792-7. PubMed ID: 19938140
    [Abstract] [Full Text] [Related]

  • 5. Conversion from sirolimus to everolimus in kidney transplant recipients receiving a calcineurin-free regimen.
    Carvalho C, Coentrão L, Bustorff M, Patrício E, Sampaio S, Santos J, Oliveira G, Pestana M.
    Clin Transplant; 2011 Dec; 25(4):E401-5. PubMed ID: 21457330
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
    Sundberg AK, Rohr MS, Hartmann EL, Adams PL, Stratta RJ.
    Clin Transplant; 2004 Dec; 18 Suppl 12():61-6. PubMed ID: 15217410
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Everolimus in clinical practice in long-term liver transplantation: an observational study.
    Casanovas T, Argudo A, Peña-Cala MC.
    Transplant Proc; 2011 Dec; 43(6):2216-9. PubMed ID: 21839237
    [Abstract] [Full Text] [Related]

  • 12. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
    Sayin B, Karakayali H, Colak T, Sevmis S, Pehlivan S, Demirhan B, Haberal M.
    Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
    [Abstract] [Full Text] [Related]

  • 13. Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination.
    Cataneo-Dávila A, Zúñiga-Varga J, Correa-Rotter R, Alberú J.
    Transplant Proc; 2009 Dec; 41(10):4138-46. PubMed ID: 20005355
    [Abstract] [Full Text] [Related]

  • 14. Benefit of early conversion from CNI-based to everolimus-based immunosuppression in heart transplantation.
    Gude E, Gullestad L, Arora S, Simonsen S, Hoel I, Hartmann A, Holdaas H, Fiane AE, Geiran OR, Andreassen AK.
    J Heart Lung Transplant; 2010 Jun; 29(6):641-7. PubMed ID: 20304681
    [Abstract] [Full Text] [Related]

  • 15. Conversion to everolimus in liver transplant patients with renal dysfunction.
    Pérez T, Segovia R, Castro L, Roblero JP, Estela R.
    Transplant Proc; 2011 Jun; 43(6):2307-10. PubMed ID: 21839260
    [Abstract] [Full Text] [Related]

  • 16. A retrospective 12-month study of conversion to everolimus in lung transplant recipients.
    Roman A, Ussetti P, Zurbano F, Borro JM, Solé A, Carreño MC, Santos F.
    Transplant Proc; 2011 Sep; 43(7):2693-8. PubMed ID: 21911148
    [Abstract] [Full Text] [Related]

  • 17. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L.
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [Abstract] [Full Text] [Related]

  • 18. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group.
    Transplantation; 2009 Jan 27; 87(2):233-42. PubMed ID: 19155978
    [Abstract] [Full Text] [Related]

  • 19. Tolerability of everolimus-based immunosuppression in maintenance liver transplant recipients.
    Vallin M, Guillaud O, Morard I, Gagnieu MC, Mentha G, Adham M, Morelon E, Boillot O, Giostra E, Dumortier J.
    Clin Transplant; 2011 Jan 27; 25(4):660-9. PubMed ID: 21158921
    [Abstract] [Full Text] [Related]

  • 20. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results.
    Levy G, Schmidli H, Punch J, Tuttle-Newhall E, Mayer D, Neuhaus P, Samuel D, Nashan B, Klempnauer J, Langnas A, Calmus Y, Rogiers X, Abecassis M, Freeman R, Sloof M, Roberts J, Fischer L.
    Liver Transpl; 2006 Nov 27; 12(11):1640-8. PubMed ID: 16598777
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.